Turmeric as Cancer Treatment

Turmeric (Curcuma longa) is native to southern Asia. It is particularly present in the socio-cultural life of the Indian subcontinent, where it is considered as an outstanding plant thanks to its many properties: spice, food preservative, coloring, cosmetic and medicinal agent.

Turmeric has been widespread in south-east Asia since ancient times. But in recent decades it is also the subject of numerous scientific studies worldwide where scientists are constantly looking to better understand its nutritional and medical properties. Some of those studies have found turmeric has amazing cancer fighting potentiality. It can be used not only to prevent the formation of malignant tumors but also to combat reproduction and proliferation of cancerous cells.

Turmeric Cancer Prevention Properties

The potential of Curcuma longa in preventing cancers has been studied since 1985. The results of in vitro and in vivo experiments in mice showed a reduction of tumor development with the use turmeric extract and its active component, curcumin. It was also found that the extracts can inhibit cancer cell invasion and metastasis through activation of the tumor suppressor DnaJ-like heat shock protein 40.

Ever since, many other studies have been conducted on the inhibitory effects of turmeric and its active ingredient curcumin on the development of many cancers: colon, liver, lung, ovary, breast, leukemia, prostate, stomach, and pancreas. All these studies also suggest that curcumin has strong potential as an adjuvant chemotherapy agent.

According to epidemiological data, the prevalence of several cancers, including colon, breast, prostate and lung, was lower in Asian countries where people eat a lot of turmeric. In addition, numerous studies on animals exposed to cancer-causing substances (carcinogens) demonstrate that curcumin could prevent many cancers: lung, colon, stomach, liver, skin, breast, esophagus, lymphoma and leukemia.

Turmeric and Colorectal Cancer

Other researches on turmeric and cancer prevention have identified it as an effective chemopreventive agent for colorectal cancer in rodents. The first findings of these studies have led some agencies, including the American Cancer Society, to advocate the use of this powerful spice against many cancers, including colorectal Cancer.

Another study suggests the number and size of intestinal polyps of people with familial polyposis decreased under the effect of curcumin (480 mg, 3 times a day) associated with quercetin (20 mg).

Turmeric and Breast Cancer

When it comes to turmeric and breast cancer, research is very active and the results of several clinical trials are expected. But previous studies showed the antioxidant and anti-inflammatory curcumin may play a role in preventing and treating breast tumors. In vitro studies already indicate that curcumin inhibits the proliferation of cancerous cells by acting at various times in their development by promoting the production of enzymes that help the body get rid of tumoral cells.

But as for today, there are very few studies conducted on turmeric and breast cancer prevention, which makes it very difficult to reach a conventional conclusion. Clinically, data is still scarce. They were obtained with groups of no more than 25 people in the best case. Nevertheless, the results are promising. They suggest that consumption of this powerful could be associated with reduced risk of breast cancer (and others) in smokers. In people at risk, doses of 1 g to 8 g of curcumin per day for 3 months managed to regress some precancerous lesions.

Turmeric and Prostate Cancer

Prostate cancer has the highest occurrence rate among all malignant tumors. It is also the second-leading disorder causing cancer-realted death among men in the United States. As of 2015, about 30,000 men die each year of castration-resistant prostate cancer due to the inevitable progression of resistance to first-line treatment with docetaxel. So, anything that can restrain this disease must be taken into consideration.

Several researches have highlighted the therapeutic potential of curcumin (turmeric), used as a dietary supplement as a natural anti-inflammatory agent. It was shown to decrease the proliferative potential and cause the death of cancer cells in both androgen-dependent and androgen-independent prostate cancer. The safety profile of dietary curcumin in humans has been well-documented, and its therapeutic prospect in treating prostate cancer, especially for castration-resistant prostate cancer, has been evidenced in several cell culture systems and human xenograft mouse models.

Turmeric and Cancer Treatment

The anti-cancer properties of curcumin are taken very seriously by medical scientists. As of today, several clinical trials are underway, with new results come out every now and then. Although these results are very few, they are encouraging and promising. For instance, a recent one has shown curcumin (8 g daily), used alone or in combination with chemotherapy, resulted in some cases to stabilize the development of pancreatic cancer. This effect was also observed in patients suffering from colorectal cancer.

These preliminary studies have confirmed, however, studies with animals revealed the bioavailability of curcumin is very low. It is poorly absorbed from the intestines and the fraction absorbed is quickly converted and eliminated by the liver. The amounts that have proven effective in vitro experiments are difficult to achieve in the body. This is one reason why clinical trials using doses so important and focus on cancers of the digestive tract where the amount of curcumin remain high.

Turmeric can also be used as an adjuvant to conventional cancer treatments. Many results obtained in vitro or in vivo in animals indicate that the curcumin increases the therapeutic effects of radiation and chemotherapy by rendering cancer cells more sensitive to these treatments. It could also reduce their side effects.


  1. Yigang Feng, Ning Wang, Fan Cheung, Meifen Zhu, Hongyun Li and Yibin Feng, « Molecular and Cellular Mechanism Studies on Anticancer Effects of Chinese Medicine », Biomedical Engineering, Trends, Research and Technologies,‎ 8 janvier 2011, p. 5-7 [ archive])
  2. Mohammad Farazuddin et al., « Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals », International Journal of Nanomedicine, no Volume 9, Issue 1,‎ 3 mars 2014 [ archive])
  3. Po-Ming Chen et al., « MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway », Free Radical Biology and Medicine, no 77,‎ 11 décembre 2014  [ archive])
  4. Padmamalini Thulasiraman et al., « Curcumin restores sensitivity to retinoic acid in triple negative breast cancer cells », BMC Cancer, no 14:724,‎ 2014 [ archive])
  5. Choi HY, Lim JE, Hong JH., « Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. », Prostate Cancer and Prostatic Diseases, no Volume 13, Issue 4,‎ décembre 2010 [ archive])
  6. Rakesh K. Srivastava, Qinghe Chen, Imtiaz Siddiqui, Krishna Sarva & Sharmila Shankar, « Linkage of Curcumin-Induced Cell Cycle Arrest and Apoptosis by Cyclin-Dependent Kinase Inhibitor p21/WAF1/CIP1 », Cell Cycle, no Volume 6, Issue 23,‎ 2007 [ archive])
  7. Lu B, Yu L, Xu L, Chen H, Zhang L, Zeng Y., « The effects of radix curcumae extract on expressions of VEGF, COX-2 and PCNA in gastric mucosa of rats fed with MNNG. », Current Pharmaceutical Biotechnology, no 11,‎ avril 2010 [archive])
  8. R. P. Sahu, S. Batra and S. K. Srivastava, « Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells » , British Journal of Cancer , no 100,‎ 28 avril 2009 [ archive] )
  9. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Hanai H, Iida T, Takeuchi K, et alClin Gastroenterol Hepatol. 2006 Dec;4(12):1502-6.
  10. Chauhan DP. Chemotherapeutic potential of curcumin for colorectal cancer.Curr Pharm Des 2002;8(19):1695-706.
  11. 14. Moss Ralph. Curries and Cancer Rates. The Moss Reports, 0ctober 23, 2002. http://cancerdecisions.com [Consulté le 29 mars 2011]
  12. Anticancer and carcinogenic properties of curcumin: considerations for its clinical development as a cancer chemopreventive and chemotherapeutic agent. López-Lázaro M. Nutr Food Res. 2008 Jun;52 Suppl 1:S103-27. Review.
  13. Polasa K, Raghuram TC, et alEffect of turmeric on urinary mutagens in smokers.Mutagenesis 1992 Mar;7(2):107-9.
  14. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Cheng AL, Hsu CH, et alAnticancer Res. 2001 Jul-Aug;21(4B):2895-900.
  15. Cancer chemopreventive effects of curcumin. Surh YJ, Chun KS. Adv Exp Med Biol. 2007;595:149-72. Review.
  16. Garcea G, Jones DJ, et alDetection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration . Br J Cancer. 2004 Mar 8;90(5):1011-5.
  17. Garcea G, Berry DP, et alConsumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequencesCancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):120-5. Integral text: http://cebp.aacrjournals.org

    21. New mechanisms and therapeutic potential of curcumin for colorectal cancer. Villegas I, Sánchez-Fidalgo S, et al.Mol Nutr Food Res. 2008 Sep;52(9):1040-61. Review.

  18. Phase II trial of curcumin in patients with advanced pancreatic cancer. Dhillon N, Aggarwal BB, et alClin Cancer Res. 2008 Jul 15;14(14):4491-9.
  19. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Reuter S, Eifes S, et alBiochem Pharmacol. 2008 Dec 1;76(11):1340-51. Review.
  20. 27. US National Institutes of Health. Trial of Curcumin and Cancer. [Consulté le 29 mars 2011] http://clinicaltrials.gov
  21. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Bar-Sela G, Epelbaum R, Schaffer M. Curr Med Chem. 2010;17(3):190-7.
  22. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis. Cruz-Correa M, Shoskes DA, et alClin Gastroenterol Hepatol. 2006 Aug;4(8):1035-8.
  23. Thamlikitkul V, Bunyapraphatsara N, et alRandomized double blind study of Curcuma domestica Val. for dyspepsia.J Med Assoc Thai 1989 Nov;72(11):613-20.
  24. US National Institutes of Health. Curcumin (Tumeric) in the Treatment of Irritable Bowel Syndrome: A Randomized-Controlled Trial (CuTIBS) [retrieved march 29, 2016] http://clinicaltrials.gov
  25. US National Institutes of Health. Curcumin and Alzheimer [retrieved march 2016] http://clinicaltrials.gov
  26. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Sharma RA, McLelland HR, et alClin Cancer Res. 2001 Jul;7(7):1894-900.
  27. Perspectives on chemopreventive and therapeutic potential of curcumin analogs in medicinal chemistry. Padhye S, Chavan D, et alMini Rev Med Chem. 2010 May;10(5):372-87. Review.
  28. Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. Goel A, Aggarwal BB. Nutr Cancer. 2010 Oct;62(7):919-30. Review.
  29. Efficacy and safety of Meriva®, a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients. Belcaro G, Cesarone MR, et alAltern Med Rev. 2010 Dec;15(4):337-44.
  30. Curcumin therapy in inflammatory bowel disease: a pilot study. Holt PR, Katz S, Kirshoff R. Dig Dis Sci. 2005 Nov;50(11):2191-3.
  31. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Epelbaum R, Schaffer M, et alNutr Cancer. 2010;62(8):1137-41.

Leave a Reply